secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001140361-25-044148
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin reports NAVIGATE biomarker data consistent with clinical benefit; FDA package submitted
--------------------------------------------------------------------------------

- In patients with ELF >11.3 (high-risk), new varices occurred in 22.7% on belapectin vs 42.9% on placebo.
- PRO-C3, a marker of fibrogenesis, showed >50% reduction from baseline with belapectin 2 mg/kg vs placebo at 18 months.
- Belapectin reduced progression of liver stiffness on FibroScan (≥30% increase or ≥5 kPa rise) vs placebo.
- No drug-related serious adverse events; discontinuation rates similar to placebo in NAVIGATE.
- FDA package submitted; company exploring strategic partnerships and extended cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125044148/0001140361-25-044148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125044148/ef20060348_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-044148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer